{"id":334126,"date":"2020-06-01T01:00:00","date_gmt":"2020-05-31T23:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/now-also-available-as-a-patient-friendly-ready-to-use-pen\/"},"modified":"2020-06-01T01:00:00","modified_gmt":"2020-05-31T23:00:00","slug":"now-also-available-as-a-patient-friendly-ready-to-use-pen","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/now-also-available-as-a-patient-friendly-ready-to-use-pen\/","title":{"rendered":"Now also available as a patient-friendly ready-to-use pen"},"content":{"rendered":"

The device, which was recently approved by Swissmedic, enables psoriasis sufferers to self-administer the biologic in single doses. It is currently the only IL23 inhibitor available in Switzerland in the form of a patient-controlled injector. <\/strong><\/p>\n

<\/p>\n

The new TREMFYA\u00ae prefabricated<\/sup> pen [1] is not an autoinjector as with other biologics in the therapy of moderate to severe plaque psoriasis. The innovative design of the TREMFYA\u00ae prefabricated<\/sup> pen allows patients to control the intensity and pressure of their injection themselves. In the ORION study, nearly 99% of patients reported a successful first injection [2]. In addition, the pre-filled pen includes a safety system to protect the needle after use. Even after three injections, patients in the study continued to rate the use of the TREMFYA\u00ae<\/sup> pen as positive [2].  <\/p>\n

Convincingly simple handling<\/h2>\n

Psoriasis patients sometimes have difficulty with self-administered forms of treatment due to a number of factors. In the randomized phase III ORION trial [2] conducted at multiple study sites, patients’ subjective assessment in this regard was evaluated using a validated questionnaire (Self-Injection Assessment Questionnaire, SIAQ) [3]. This involved assessing patients’ experiences with the TREMFYA\u00ae prefabricated<\/sup> pen at weeks 0, 4, and 12 on a scale of 0 (“worst”) to 10 (“best”) using the following six criteria:<\/p>\n